{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:44:24Z","timestamp":1760147064676,"version":"build-2065373602"},"reference-count":63,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence for the benefits of treating hepatitis C virus cirrhotic patients, but there is still some need for clarification concerning the real impact on the long-term evolution after achieving sustained virological response; there is no general consensus in the literature about identifying the patients that do not improve post-treatment. Materials and Methods: Our retrospective analysis investigated the long-term (2 years) evolution of 46 patients with cirrhosis with thrombocytopenia, previously infected with VHC, treated and who obtained an SVR after DAA treatment. Results: Despite the overall improvement, 8.7% patients developed hepatocellular carcinoma and 6.5% patients ascites\/upper GI bleeding. We found that FIB-4, MELD and AFP changes at 1 year were the most significant predictors for these outcomes. Additionally, a drop in leukocyte count after 1 year seemed to indicate a risk for hepatocellular carcinoma, but this was not consistent. Conclusions: It might be beneficial to intensify the surveillance for post-treatment adverse liver effects for the patients with these marker changes at 1 year.<\/jats:p>","DOI":"10.3390\/medicina59010146","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T01:32:26Z","timestamp":1673487146000},"page":"146","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-3902","authenticated-orcid":false,"given":"Secil","family":"Omer","sequence":"first","affiliation":[{"name":"Department of Medical Semiology, Saint Joan Hospital Bucharest, Carol Davila University of Medicine, 042122 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-1789","authenticated-orcid":false,"given":"Adrian","family":"Iftime","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Carol Davila University of Medicine, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transplant Immunology, Fundeni Clinical Institute Bucharest, Carol Davila University of Medicine, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Dina","sequence":"additional","affiliation":[{"name":"Department of Medical Semiology, Saint Joan Hospital Bucharest, Carol Davila University of Medicine, 042122 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"ref_1","unstructured":"Polaris Observatory HCV Collaborators (2017). Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study. Lancet. Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP3077","article-title":"Why Is Viral Eradication so Important in Patients with HCV-related Cirrhosis?","volume":"22","author":"Velosa","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_3","unstructured":"Chopra, S., and Clinical Manifestations and Natural History of Chronic Hepatitis C Virus Infection (2022, December 31). UpToDate, Wolters Kluwer (Ed. Di Bisceglie A.M. and Bloom A.). Available online: https:\/\/www.uptodate.com\/contents\/clinical-manifestations-and-natural-history-of-chronic-hepatitis-c-virus-infection."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14218\/JCTH.2020.00007","article-title":"Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review","volume":"8","author":"Rawi","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_5","unstructured":"Intagliata, N., and Shah, N.L. (2022, December 31). Hemostatic Abnormalities in Patients with Liver Disease. UpToDate, Wolters Kluwer (Ed. Leung L.L.K. and Tirnauer J.S.). Available online: https:\/\/www.uptodate.com\/contents\/hemostatic-abnormalities-in-patients-with-liver-disease."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2010.01366.x","article-title":"Prevalence of thrombocytopenia among patients with chronic hepatitis C: A systematic review","volume":"18","author":"Louie","year":"2010","journal-title":"J. Viral Hepat."},{"key":"ref_7","first-page":"1028","article-title":"Follow-up of Sustained Virological Responders with Hepatitis C and Advanced Liver Disease after Interferon\/Ribavirin-Free Treatment","volume":"38","author":"Kozbial","year":"2018","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between Sustained Virological Response and All-Cause Mortality among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"European Association for Study of Liver (2015). EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol., 63, 199\u2013236.","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hepr.12331","article-title":"Progressive Fibrosis Significantly Correlates with Hepatocellular Carcinoma in Patients with a Sustained Virological Response","volume":"45","author":"Tachi","year":"2015","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow Regression of Liver Fibrosis Presumed by Repeated Biomarkers after Virological Cure in Patients with Chronic Hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained Virologic Response to Interferon-Free Therapies Ameliorates HCV-induced Portal Hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of Fibrosis and Portal Hypertension in HCV-associated Cirrhosis and Sustained Virologic Response after Interferon-Free Antiviral Therapy","volume":"23","author":"Knop","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chekuri, S., Nickerson, J., Bichoupan, K., Sefcik, R., Doobay, K., Chang, S., DelBello, D., Harty, A., Dieterich, D.T., and Perumalswami, P.V. (2016). Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159413"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0168-8278(17)30475-0","article-title":"Degree of Liver Fibrosis Regression Predicted by Transient Elastography after Cure of Chronic Hepatitis C with Direct Acting Antivirals Is Overestimated but Confirmed by Liver Biopsy","volume":"66","author":"Pockros","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"ANRS CO13 HEPAVIH Cohort (2015). Regression of Liver Stiffness after Sustained Hepatitis C Virus (HCV) Virological Responses among HIV\/HCV-coinfected Patients. AIDS, 29, 1821\u20131830.","DOI":"10.1097\/QAD.0000000000000787"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical Outcomes of Patients Undergoing Antiviral Therapy While Awaiting Liver Transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical Outcomes Following DAA Therapy in Patients with HCV-related Cirrhosis Depend on Disease Severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the Oesophagus for Bleeding Oesophageal Varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"key":"ref_23","unstructured":"R Core Team (2021, May 18). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wickham, H. (2016). Ggplot2: Elegant Graphics for Data Analysis, Springer.","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"key":"ref_26","unstructured":"Heinze, G., Ploner, M., and Jiricka, L. (2021, January 18). Logistf: Firth\u2019s Bias-Reduced Logistic Regression. R Package Manual Version 1.24. Available online: https:\/\/cran.r-project.org\/package=logistf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias Reduction of Maximum Likelihood Estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Venables, V.N., and Ripley, B.D. (2002). Modern Applied Statistics with S, Springer. [4th ed.].","DOI":"10.1007\/978-0-387-21706-2"},{"key":"ref_29","first-page":"1044","article-title":"Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection","volume":"14","author":"Lu","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A Morphometric and Immunohistochemical Study to Assess the Benefit of a Sustained Virological Response in Hepatitis C Virus Patients with Cirrhosis","volume":"56","author":"Aghemo","year":"2012","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio, R., Degasperi, E., Aghemo, A., Fraquelli, M., Lampertico, P., Rumi, M.G., Facchetti, F., Grassi, E., Casazza, G., and Rosenberg, W. (2016). Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155967"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of Liver Transplant Candidates with Chronic Hepatitis C after Viral Eradication: A European Study","volume":"65","author":"Belli","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_33","first-page":"2170","article-title":"Delisting HCV-infected Liver Transplant Candidates Who Improved after Viral Eradication: Outcome 2 Years after Delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_34","unstructured":"Lee, C.I., and Elmore, J.G. (2022, December 31). Radiation-Related Risks of Imaging. UpToDate, Wolters Kluwer (Ed. Givens J. and D\u2019Aronson M.). Available online: https:\/\/www.uptodate.com\/contents\/radiation-related-risks-of-imaging."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503074","article-title":"Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort","volume":"27","author":"Fragoso","year":"2020","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_36","first-page":"1017","article-title":"A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma after Treatment of Hepatitis C Virus Infection","volume":"13","author":"Chang","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciw362","article-title":"Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C","volume":"63","author":"Hedenstierna","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/j.1572-0241.1999.01151.x","article-title":"A Predictive Model for The Development of Hepatocellular Carcinoma, Liver Failure, Or Liver Transplantation for Patients Presenting To Clinic With Chronic Hepatitis C","volume":"94","author":"Bonis","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected High Rate of Early Tumor Recurrence in Patients with HCV-related HCC Undergoing Interferon-Free Therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular Carcinoma Risk Following Direct-Acting Antiviral HCV Therapy: A Systematic Review, Meta-Analyses, and Meta-Regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.14823","article-title":"Systematic Review with Meta-Analysis: Recurrence of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy","volume":"48","author":"Saraiya","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A Risk for Hepatocellular Carcinoma Persists Long-Term after Sustained Virologic Response in Patients with Hepatitis C-associated Liver Cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of Hepatocellular Carcinoma after Sustained Virological Response in Veterans with Hepatitis C Virus Infection","volume":"64","author":"Kanwal","year":"2016","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10620-014-3050-5","article-title":"All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C","volume":"59","author":"Dieperink","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/jir.2019.0049","article-title":"Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy","volume":"39","author":"Na","year":"2019","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000490360","article-title":"HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection","volume":"8","author":"Schlevogt","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_49","first-page":"74","article-title":"Intrahepatic Immune Changes after Hepatitis c Virus Eradication by Direct-Acting Antiviral Therapy","volume":"40","author":"Amaddeo","year":"2020","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.15403\/jgld-309","article-title":"Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C","volume":"28","author":"Simili","year":"2019","journal-title":"J. Gastrointest. Liver Dis. JGLD"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/hepr.13307","article-title":"Association of Serum Interferon-\u039b3 Levels with Hepatocarcinogenesis in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents","volume":"49","author":"Murakawa","year":"2019","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jgh.14359","article-title":"Association of Serial Serum Major Histocompatibility Complex Class I Chain-Related A Measurements with Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Viral Eradication","volume":"34","author":"Huang","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2017.01.041","article-title":"Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection","volume":"152","author":"Matsuura","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00535-018-1526-3","article-title":"TLL1 Variant Associated with Development of Hepatocellular Carcinoma after Eradication of Hepatitis C Virus by Interferon-Free Therapy","volume":"54","author":"Iio","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/j.gastro.2017.04.056","article-title":"TLL1 Rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C","volume":"153","author":"John","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/jvh.13155","article-title":"TLL1 Variants Do Not Predict Hepatocellular Carcinoma Development in HCV Cirrhotic Patients Treated with Direct-Acting Antivirals","volume":"26","author":"Degasperi","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijid.2016.02.025","article-title":"The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection","volume":"45","author":"Meng","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wu, Y.L., Fulgenzi, C.A.M., D\u2019Alessio, A., Cheon, J., Nishida, N., Saeed, A., Wietharn, B., Cammarota, A., Pressiani, T., and Personeni, N. (2022). Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers, 14.","DOI":"10.3390\/cancers14235834"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2017.07.007","article-title":"Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection","volume":"51","author":"Zhao","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/MEG.0000000000002439","article-title":"The correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with nonalcoholic fatty liver disease: A cross-sectional study","volume":"34","author":"Zhou","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kawagishi, N., Suda, G., Nakamura, A., Kimura, M., Maehara, O., Suzuki, K., Nakamura, A., Ohara, M., Izumi, T., and Umemura, M. (2018). Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLOS ONE, 13.","DOI":"10.1371\/journal.pone.0209615"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ramadan, M.S., Boccia, F., Moretto, S.M., Gregorio, F.D., Gagliardi, M., Iossa, D., Durante-Mangoni, E., and Zampino, R. (2022). Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195781"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Graf, C., Welzel, T., Bogdanou, D., Vermehren, J., Beckel, A., Bojunga, J., Friedrich-Rust, M., Dietz, J., Kubesch, A., and Mondorf, A. (2020). Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092702"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/146\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:03:24Z","timestamp":1760119404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["medicina59010146"],"URL":"https:\/\/doi.org\/10.3390\/medicina59010146","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}